3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||111.148 g·mol−1|
|Melting point||83.5 °C (182.3 °F; 356.6 K)|
|Boiling point||209.5 °C (409.1 °F; 482.6 K)|
|Easily soluble in cold water, hot water|
|Solubility in other solvents||Easily soluble in methanol. Very slightly soluble in diethyl ether. Easily soluble in ethanol.|
|Acidity (pKa)||Imidazole: 6.04 |
Terminal NH2: 9.75
|L03AX14 (WHO) V04CG03 (WHO) (phosphate)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Histamine is an organic nitrogenous compound involved in local immune responses, as well as regulating physiological function in the gut and acting as a neurotransmitter for the brain, spinal cord, and uterus. Since histamine was discovered in 1910, it has been considered as a local hormone (autocoid) because it lacks the classic endocrine glands to secrete it, however, in recent years, histamine has been recognized as a central neurotransmitter. Histamine is involved in the inflammatory response and has a central role as a mediator of itching. As part of an immune response to foreign pathogens, histamine is produced by basophils and by mast cells found in nearby connective tissues. Histamine increases the permeability of the capillaries to white blood cells and some proteins, to allow them to engage pathogens in the infected tissues. It consists of an imidazole ring attached to an ethylamine chain; under physiological conditions, the amino group of the side-chain is protonated.
Histamine base, obtained as a mineral oil mull, melts at 83–84 °C. Hydrochloride and phosphorus salts form white hygroscopic crystals and are easily dissolved in water or ethanol, but not in ether. In aqueous solution, the imidazole ring of histamine exists in two tautomeric forms, identified by which of the two nitrogen atoms is protonated. The nitrogen farther away from the side chain is the 'tele' nitrogen and is denoted by a lowercase tau sign and the nitrogen closer to the side chain is the 'pros' nitrogen and is denoted by the pi sign. The tele tautomer, Nτ-H-histamine, is preferred in solution as compared to the pros tautomer, Nπ-H-histamine.
Histamine has two basic centres, namely the aliphatic amino group and whichever nitrogen atom of the imidazole ring does not already have a proton. Under physiological conditions, the aliphatic amino group (having a pKa around 9.4) will be protonated, whereas the second nitrogen of the imidazole ring (pKa ≈ 5.8) will not be protonated. Thus, histamine is normally protonated to a singly charged cation. Since human blood is slightly basic (with a normal pH range of 7.35 to 7.45) therefore the predominant form of histamine present in human blood is monoprotic at the aliphatic nitrogen. Histamine is a monoamine neurotransmitter.
Synthesis and metabolism
Once formed, histamine is either stored or rapidly inactivated by its primary degradative enzymes, histamine-N-methyltransferase or diamine oxidase. In the central nervous system, histamine released into the synapses is primarily broken down by histamine-N-methyltransferase, while in other tissues both enzymes may play a role. Several other enzymes, including MAO-B and ALDH2, further process the immediate metabolites of histamine for excretion or recycling.
Bacteria also are capable of producing histamine using histidine decarboxylase enzymes unrelated to those found in animals. A non-infectious form of foodborne disease, scombroid poisoning, is due to histamine production by bacteria in spoiled food, particularly fish. Fermented foods and beverages naturally contain small quantities of histamine due to a similar conversion performed by fermenting bacteria or yeasts. Sake contains histamine in the 20–40 mg/L range; wines contain it in the 2–10 mg/L range.
Storage and release
Most histamine in the body is generated in granules in mast cells and in white blood cells (leukocytes) called basophils. Mast cells are especially numerous at sites of potential injury — the nose, mouth, and feet, internal body surfaces, and blood vessels. Non-mast cell histamine is found in several tissues, including the hypothalamus region of the brain, where it functions as a neurotransmitter. Another important site of histamine storage and release is the enterochromaffin-like (ECL) cell of the stomach.
The most important pathophysiologic mechanism of mast cell and basophil histamine release is immunologic. These cells, if sensitized by IgE antibodies attached to their membranes, degranulate when exposed to the appropriate antigen. Certain amines and alkaloids, including such drugs as morphine, and curare alkaloids, can displace histamine in granules and cause its release. Antibiotics like polymyxin are also found to stimulate histamine release.
Histamine release occurs when allergens bind to mast-cell-bound IgE antibodies. Reduction of IgE overproduction may lower the likelihood of allergens finding sufficient free IgE to trigger a mast-cell-release of histamine.
Histamine is released by mast cells as an immune response and is later degraded primarily by two enzymes: diamine oxidase (DAO), coded by AOC1 genes, and histamine-N-methyltransferase (HNMT), coded by the HNMT gene. The presence of single nucleotide polymorphisms (SNPs) at these genes are associated with a wide variety of disorders caused by an overactive immune system, from ulcerative colitis to autism spectrum disorder (ASD). Histamine degradation is crucial to the prevention of allergic reactions to otherwise harmless substances.
DAO is typically expressed in epithelial cells at the tip of the villus of the small intestine mucosa. Reduced DAO activity is associated with gastrointestinal disorders and widespread food intolerances. This is due to an increase in histamine absorption through enterocytes, which increases histamine concentration in the bloodstream. One study found that migraine patients with gluten sensitivity were positively correlated with having lower DAO serum levels. Low DAO activity can have more severe consequences as mutations in the ABP1 alleles of the AOC1 gene have been associated with ulcerative colitis. Heterozygous or homozygous recessive genotypes at the rs2052129, rs2268999, rs10156191 and rs1049742 alleles increased the risk for reduced DAO activity. People with genotypes for reduced DAO activity can avoid foods high in histamine, such as alcohol, fermented foods, and aged foods, to attenuate any allergic reactions. Additionally, they should be aware whether any probiotics they are taking contain any histamine-producing strains and consult with their doctor to receive proper support.
HNMT is expressed in the central nervous system, where deficiencies have been shown to lead to aggressive behavior and abnormal sleep-wake cycles in mice. Since brain histamine as a neurotransmitter regulates a number of neurophysiological functions, emphasis has been placed on the development of drugs to target histamine regulation. Yoshikawa et al. explores how the C314T, A939G, G179A, and T632C polymorphisms all impact HNMT enzymatic activity and the pathogenesis of various neurological disorders. These mutations can have either a positive or negative impact. Some patients with ADHD have been shown to exhibit exacerbated symptoms in response to food additives and preservatives, due in part to histamine release. In a double-blind placebo-controlled crossover trial, children with ADHD who responded with aggravated symptoms after consuming a challenge beverage were more likely to have HNMT polymorphisms at T939C and Thr105Ile. Histamine’s role in neuroinflammation and cognition has made it a target of study for many neurological disorders, including autism spectrum disorder (ASD). De novo deletions in the HNMT gene have also been associated with ASD.
Mast cells serve an important immunological role by defending the body from antigens and maintaining homeostasis in the gut microbiome. They act as an alarm to trigger inflammatory responses by the immune system. Their presence in the digestive system enables them to serve as an early barrier to pathogens entering the body. People who suffer from widespread sensitivities and allergic reactions may have mast cell activation syndrome (MCAS), in which excessive amounts of histamine are released from mast cells, and cannot be properly degraded. The abnormal release of histamine can be caused by either dysfunctional internal signals from defective mast cells or by the development of clonal mast cell populations through mutations occurring in the tyrosine kinase Kit. In such cases, the body may not be able to produce sufficient degradative enzymes to properly eliminate the excess histamine. Since MCAS is symptomatically characterized as such a broad disorder, it is difficult to diagnose and can be mislabeled as a variety of diseases, including irritable bowel syndrome and fibromyalgia.
Histamine is often explored as a potential cause for diseases related to hyper-responsiveness of the immune system. In patients with asthma, abnormal histamine receptor activation in the lungs is associated with bronchospasm, airway obstruction, and production of excess mucus. Mutations in histamine degradation are more common in patients with a combination of asthma and allergen hypersensitivity than in those with just asthma. The HNMT-464 TT and HNMT-1639 TT are significantly more common among children with allergic asthma, the latter of which is overrepresented in African-American children.
Mechanism of action
In humans, histamine exerts its effects primarily by binding to G protein-coupled histamine receptors, designated H1 through H4. As of 2015, histamine is believed to activate ligand-gated chloride channels in the brain and intestinal epithelium.
|G-protein coupled receptor||Location||Function||Sources|
|Histamine H1 receptor||
• CNS: Expressed on the dendrites of the output neurons of the histaminergic tuberomammillary nucleus, which projects to the dorsal raphe, locus coeruleus, and additional structures.
• CNS: Sleep-wake cycle (promotes wakefulness), body temperature, nociception, endocrine homeostasis, regulates appetite, involved in cognition
|Histamine H2 receptor||
• CNS: Dorsal striatum (caudate nucleus and putamen), cerebral cortex (external layers), hippocampal formation, dentate nucleus of the cerebellum
• CNS: Not established (note: most known H2 receptor ligands are unable to cross the blood–brain barrier in sufficient concentrations to allow for neuropsychological and behavioral testing)
|Histamine H3 receptor||Located in the central nervous system and to a lesser extent peripheral nervous system tissue||Autoreceptor and heteroreceptor functions: decreased neurotransmitter release of histamine, acetylcholine, norepinephrine, serotonin. Modulates nociception, gastric acid secretion, and food intake.|||
|Histamine H4 receptor||Located primarily on basophils and in the bone marrow. It is also expressed in the thymus, small intestine, spleen, and colon.||Plays a role in mast cell chemotaxis, itch perception, cytokine production and secretion, and visceral hypersensitivity. Other putative functions (e.g., inflammation, allergy, cognition, etc.) have not been fully characterized.|||
|Ligand-gated ion channel||Location||Function||Sources|
|Histamine-gated chloride channel||Putatively: CNS (hypothalamus, thalamus) and intestinal epithelium||Brain: Produces fast inhibitory postsynaptic potentials
Intestinal epithelium: chloride secretion (associated with secretory diarrhea)
Roles in the body
Although histamine is small compared to other biological molecules (containing only 17 atoms), it plays an important role in the body. It is known to be involved in 23 different physiological functions. Histamine is known to be involved in many physiological functions because of its chemical properties that allow it to be versatile in binding. It is Coulombic (able to carry a charge), conformational, and flexible. This allows it to interact and bind more easily.
Vasodilation and fall in blood pressure
It has been known for more than one hundred years that an intravenous injection of histamine causes a fall in the blood pressure. The underlying mechanism concerns both vascular hyperpermeability and vasodilation. Histamine binding to endothelial cells causes them to contract, thus increasing vascular leak. It also stimulates synthesis and release of various vascular smooth muscle cell relaxants, such as nitric oxide, endothelium-derived hyperpolarizing factors and other compounds, resulting in blood vessel dilation. These two mechanisms play a key role in the pathophysiology of anaphylaxis.
Effects on nasal mucous membrane 
Increased vascular permeability causes fluid to escape from capillaries into the tissues, which leads to the classic symptoms of an allergic reaction: a runny nose and watery eyes. Allergens can bind to IgE-loaded mast cells in the nasal cavity's mucous membranes. This can lead to three clinical responses:
- sneezing due to histamine-associated sensory neural stimulation
- hyper-secretion from glandular tissue
- nasal congestion due to vascular engorgement associated with vasodilation and increased capillary permeability
Histamine is a neurotransmitter that is released from histaminergic neurons which project out of the mammalian hypothalamus. The cell bodies of these neurons are located in a portion of the posterior hypothalamus known as the tuberomammillary nucleus (TMN). The histamine neurons in this region comprise the brain's histamine system, which projects widely throughout the brain and includes axonal projections to the cortex, medial forebrain bundle, other hypothalamic nuclei, medial septum, the nucleus of the diagonal band, ventral tegmental area , amygdala, striatum, substantia nigra, hippocampus, thalamus and elsewhere. The histamine neurons in the TMN are involved in regulating the sleep-wake cycle and promote arousal when activated. The neural firing rate of histamine neurons in the TMN is strongly positively correlated with an individual's state of arousal. These neurons fire rapidly during periods of wakefulness, fire more slowly during periods of relaxation/tiredness, and stop firing altogether during REM and NREM (non-REM) sleep.
First-generation H1 antihistamines (i.e., antagonists of histamine receptor H1) are capable of crossing the blood–brain barrier and produce drowsiness by antagonizing histamine H1 receptors in the tuberomammillary nucleus. The newer class of second-generation H1 antihistamines do not readily permeate the blood–brain barrier and thus are less likely to cause sedation, although individual reactions, concomitant medications and dosage may increase the likelihood of a sedating effect. In contrast, histamine H3 receptor antagonists increase wakefulness. Similar to the sedative effect of first-generation H1 antihistamines, an inability to maintain vigilance can occur from the inhibition of histamine biosynthesis or the loss (i.e., degeneration or destruction) of histamine-releasing neurons in the TMN.
Gastric acid release
Enterochromaffin-like cells, located within the gastric glands of the stomach, release histamine that stimulates nearby parietal cells by binding to the apical H2 receptor. Stimulation of the parietal cell induces the uptake of carbon dioxide and water from the blood, which is then converted to carbonic acid by the enzyme carbonic anhydrase. Inside the cytoplasm of the parietal cell, the carbonic acid readily dissociates into hydrogen and bicarbonate ions. The bicarbonate ions diffuse back through the basilar membrane and into the bloodstream, while the hydrogen ions are pumped into the lumen of the stomach via a K+/H+ ATPase pump. Histamine release is halted when the pH of the stomach starts to decrease. Antagonist molecules, like ranitidine, block the H2 receptor and prevent histamine from binding, causing decreased hydrogen ion secretion.
While histamine has stimulatory effects upon neurons, it also has suppressive ones that protect against the susceptibility to convulsion, drug sensitization, denervation supersensitivity, ischemic lesions and stress. It has also been suggested that histamine controls the mechanisms by which memories and learning are forgotten.
Erection and sexual function
Libido loss and erectile failure can occur during treatment with histamine H2 receptor antagonists such as cimetidine, ranitidine, and risperidone. The injection of histamine into the corpus cavernosum in men with psychogenic impotence produces full or partial erections in 74% of them. It has been suggested that H2 antagonists may cause sexual difficulties by reducing the functional binding of testosterone to its endogenous receptors.
Metabolites of histamine are increased in the cerebrospinal fluid of people with schizophrenia, while the efficiency of H1 receptor binding sites is decreased. Many atypical antipsychotic medications have the effect of increasing histamine production, because histamine levels seem to be imbalanced in people with that disorder.
Histamine therapy for treatment of multiple sclerosis is currently being studied. The different H receptors have been known to have different effects on the treatment of this disease. The H1 and H4 receptors, in one study, have been shown to be counterproductive in the treatment of MS. The H1 and H4 receptors are thought to increase permeability in the blood-brain barrier, thus increasing infiltration of unwanted cells in the central nervous system. This can cause inflammation, and MS symptom worsening. The H2 and H3 receptors are thought to be helpful when treating MS patients. Histamine has been shown to help with T-cell differentiation. This is important because in MS, the body's immune system attacks its own myelin sheaths on nerve cells (which causes loss of signaling function and eventual nerve degeneration). By helping T cells to differentiate, the T cells will be less likely to attack the body's own cells, and instead, attack invaders.
As an integral part of the immune system, histamine may be involved in immune system disorders and allergies. Mastocytosis is a rare disease in which there is a proliferation of mast cells that produce excess histamine.
Some people may accumulate excessive dietary histamine in their bodies as a result of histamine intolerance. This may lead to sympthoms such as hives, itchy or flushed skin, red eyes, facial swelling, runny nose and congestion, headaches, or asthma attacks.
The properties of histamine, then called β-iminazolylethylamine, were first described in 1910 by the British scientists Henry H. Dale and P.P. Laidlaw. By 1913 the name histamine was in use, using combining forms of histo- + amine, yielding "tissue amine".
"H substance" or "substance H" are occasionally used in medical literature for histamine or a hypothetical histamine-like diffusible substance released in allergic reactions of skin and in the responses of tissue to inflammation.
- Diamine oxidase
- Hay fever (allergic rhinitis)
- Histamine intolerance
- Histamine receptor antagonist
- Scombroid food poisoning
- Photic sneeze reflex
- Histamine Material Safety Data Sheet (Technical report). sciencelab.com. 2013-05-21. Archived from the original on 2012-03-24.
- Vuckovic D, Pawliszyn J (March 2011). "Systematic evaluation of solid-phase microextraction coatings for untargeted metabolomic profiling of biological fluids by liquid chromatography-mass spectrometry". Analytical Chemistry. 83 (6): 1944–54. doi:10.1021/ac102614v. PMID 21332182.
- Marieb E (2001). Human anatomy & physiology. San Francisco: Benjamin Cummings. pp. 414. ISBN 0-8053-4989-8.
- Nieto-Alamilla G, Márquez-Gómez R, García-Gálvez AM, Morales-Figueroa GE, Arias-Montaño JA (November 2016). "The Histamine H3 Receptor: Structure, Pharmacology, and Function". Molecular Pharmacology. 90 (5): 649–673. doi:10.1124/mol.116.104752. PMID 27563055.
- Keppel Hesselink JM (December 2015). "The terms 'autacoid', 'hormone' and 'chalone' and how they have shifted with time". Autonomic & Autacoid Pharmacology. 35 (4): 51–8. doi:10.1111/aap.12037. PMID 27028114.
- Andersen HH, Elberling J, Arendt-Nielsen L (September 2015). "Human surrogate models of histaminergic and non-histaminergic itch". Acta Dermato-Venereologica. 95 (7): 771–7. doi:10.2340/00015555-2146. PMID 26015312.
- Di Giuseppe M, Fraser D (2003). Nelson Biology 12. Toronto: Thomson Canada. p. 473. ISBN 0-17-625987-2.
- "Histamine". webbook.nist.gov. Archived from the original on 2018-04-27. Retrieved 2015-01-04.
- "Histamine dihydrochloride H7250". Sigma-Aldrich. Archived from the original on 2015-08-09.
- "Histamine phosphate" (PDF). European Pharmacopoeia (5th ed.). ISBN 9287152810. Archived from the original (PDF) on 2015-01-04. Retrieved 2015-01-04.
- Paiva TB, Tominaga M, Paiva AC (July 1970). "Ionization of histamine, N-acetylhistamine, and their iodinated derivatives". Journal of Medicinal Chemistry. 13 (4): 689–92. doi:10.1021/jm00298a025. PMID 5452432.
- Jayarajah CN, Skelley AM, Fortner AD, Mathies RA (November 2007). "Analysis of neuroactive amines in fermented beverages using a portable microchip capillary electrophoresis system" (PDF). Analytical Chemistry. 79 (21): 8162–9. doi:10.1021/ac071306s. PMID 17892274. Archived from the original (PDF) on 19 July 2011.
- Thompson JS (1990). "Significance of the intestinal gradient of diamine oxidase activity". Digestive Diseases. 8 (3): 163–8. doi:10.1159/000171249. PMID 2110876.
- Yoshikawa T, Nakamura T, Yanai K (February 2019). "Histamine N-Methyltransferase in the Brain". International Journal of Molecular Sciences. 20 (3): 737. doi:10.3390/ijms20030737. PMC 6386932. PMID 30744146.
- Griauzdaitė K, Maselis K, Žvirblienė A, Vaitkus A, Jančiauskas D, Banaitytė-Baleišienė I, et al. (September 2020). "Associations between migraine, celiac disease, non-celiac gluten sensitivity and activity of diamine oxidase". Medical Hypotheses. 142: 109738. doi:10.1016/j.mehy.2020.109738. PMID 32416409. S2CID 216303896.
- García-Martin E, Mendoza JL, Martínez C, Taxonera C, Urcelay E, Ladero JM, et al. (January 2006). "Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene". World Journal of Gastroenterology. 12 (4): 615–20. doi:10.3748/wjg.v12.i4.615. PMC 4066097. PMID 16489678.
- Maintz L, Yu CF, Rodríguez E, Baurecht H, Bieber T, Illig T, et al. (July 2011). "Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities". Allergy. 66 (7): 893–902. doi:10.1111/j.1398-9995.2011.02548.x. PMID 21488903. S2CID 205405463.
- Branco AC, Yoshikawa FS, Pietrobon AJ, Sato MN (2018-08-27). "Role of Histamine in Modulating the Immune Response and Inflammation". Mediators of Inflammation. 2018: 9524075. doi:10.1155/2018/9524075. PMC 6129797. PMID 30224900.
- Yoshikawa T, Nakamura T, Yanai K (February 2019). "Histamine N-Methyltransferase in the Brain". International Journal of Molecular Sciences. 20 (3): 737. doi:10.3390/ijms20030737. PMC 6386932. PMID 30744146.
- Stevenson J, Sonuga-Barke E, McCann D, Grimshaw K, Parker KM, Rose-Zerilli MJ, et al. (September 2010). "The role of histamine degradation gene polymorphisms in moderating the effects of food additives on children's ADHD symptoms". The American Journal of Psychiatry. 167 (9): 1108–15. doi:10.1176/appi.ajp.2010.09101529. PMID 20551163.
- Wright C, Shin JH, Rajpurohit A, Deep-Soboslay A, Collado-Torres L, Brandon NJ, et al. (May 2017). "Altered expression of histamine signaling genes in autism spectrum disorder". Translational Psychiatry. 7 (5): e1126. doi:10.1038/tp.2017.87. PMC 5534955. PMID 28485729.
- Haenisch B, Nöthen MM, Molderings GJ (November 2012). "Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics". Immunology. 137 (3): 197–205. doi:10.1111/j.1365-2567.2012.03627.x. PMC 3482677. PMID 22957768.
- Anvari S, Vyhlidal CA, Dai H, Jones BL (December 2015). "Genetic Variation along the Histamine Pathway in Children with Allergic versus Nonallergic Asthma". American Journal of Respiratory Cell and Molecular Biology. 53 (6): 802–9. doi:10.1165/rcmb.2014-0493OC. PMC 4742940. PMID 25909280.
- Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, et al. (July 2015). "International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors". Pharmacological Reviews. 67 (3): 601–55. doi:10.1124/pr.114.010249. PMC 4485016. PMID 26084539.
- Wouters MM, Vicario M, Santos J (January 2016). "The role of mast cells in functional GI disorders". Gut. 65 (1): 155–68. doi:10.1136/gutjnl-2015-309151. PMID 26194403.
- Blandina P, Munari L, Provensi G, Passani MB (2012). "Histamine neurons in the tuberomamillary nucleus: a whole center or distinct subpopulations?". Frontiers in Systems Neuroscience. 6: 33. doi:10.3389/fnsys.2012.00033. PMC 3343474. PMID 22586376.
- Stromberga Z, Chess-Williams R, Moro C (March 2019). "Histamine modulation of urinary bladder urothelium, lamina propria and detrusor contractile activity via H1 and H2 receptors". Scientific Reports. 9 (1): 3899. Bibcode:2019NatSR...9.3899S. doi:10.1038/s41598-019-40384-1. PMC 6405771. PMID 30846750.
- Maguire JJ, Davenport AP (29 November 2016). "H2 receptor". IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. Archived from the original on 21 March 2017. Retrieved 20 March 2017.
- Noszal B, Kraszni M, Racz A (2004). "Histamine: fundamentals of biological chemistry". In Falus A, Grosman N, Darvas Z (eds.). Histamine: Biology and Medical Aspects. Budapest: SpringMed. pp. 15–28. ISBN 380557715X.
- Dale HH, Laidlaw PP (December 1910). "The physiological action of beta-iminazolylethylamine". The Journal of Physiology. 41 (5): 318–44. doi:10.1113/jphysiol.1910.sp001406. PMC 1512903. PMID 16993030.
- Abbas A (2018). Cellular and molecular immunology. Elsevier. p. 447. ISBN 978-0-323-47978-3.
- Monroe EW, Daly AF, Shalhoub RF (February 1997). "Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines". The Journal of Allergy and Clinical Immunology. 99 (2): S798-806. doi:10.1016/s0091-6749(97)70128-3. PMID 9042073.
- Brady S (2012). Basic Neurochemistry - Principles of Molecular, Cellular and Medical Neurobiology. 225 Wyman Street, Waltham, MA 02451, USA: Elsevier. p. 337. ISBN 978-0-12-374947-5.CS1 maint: location (link)
- Brown RE, Stevens DR, Haas HL (April 2001). "The physiology of brain histamine". Progress in Neurobiology. 63 (6): 637–72. doi:10.1016/s0301-0082(00)00039-3. PMID 11164999. S2CID 10170830.
- Yanai K, Tashiro M (January 2007). "The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies". Pharmacology & Therapeutics. 113 (1): 1–15. doi:10.1016/j.pharmthera.2006.06.008. PMID 16890992.
- Alvarez EO (May 2009). "The role of histamine on cognition". Behavioural Brain Research. 199 (2): 183–9. doi:10.1016/j.bbr.2008.12.010. PMID 19126417. S2CID 205879131.
- White JM, Rumbold GR (1988). "Behavioural effects of histamine and its antagonists: a review". Psychopharmacology. 95 (1): 1–14. doi:10.1007/bf00212757. PMID 3133686. S2CID 23148946.
- Cará AM, Lopes-Martins RA, Antunes E, Nahoum CR, De Nucci G (February 1995). "The role of histamine in human penile erection". British Journal of Urology. 75 (2): 220–4. doi:10.1111/j.1464-410X.1995.tb07315.x. PMID 7850330.
- Ito C (2004). "The role of the central histaminergic system on schizophrenia". Drug News & Perspectives. 17 (6): 383–7. doi:10.1358/dnp.2004.17.6.829029. PMID 15334189.
Many atypical antipsychotics also increased histamine turnovers.
- Jadidi-Niaragh F, Mirshafiey A (September 2010). "Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis". Neuropharmacology. 59 (3): 180–9. doi:10.1016/j.neuropharm.2010.05.005. PMID 20493888. S2CID 7852375.
- Zampeli E, Tiligada E (May 2009). "The role of histamine H4 receptor in immune and inflammatory disorders". British Journal of Pharmacology. 157 (1): 24–33. doi:10.1111/j.1476-5381.2009.00151.x. PMC 2697784. PMID 19309354.
- Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. (July 2001). "Diagnostic criteria and classification of mastocytosis: a consensus proposal". Leukemia Research. 25 (7): 603–25. doi:10.1016/S0145-2126(01)00038-8. PMID 11377686.
- "Food Sensitivity? or Histamine Intolerance? | ENT and Allergy Associates". ENT & Allergy Associates, LLP. Retrieved 2021-06-28.
- Dale HH, Laidlaw PP (December 1910). "The physiological action of beta-iminazolylethylamine". The Journal of Physiology. 41 (5): 318–44. doi:10.1113/jphysiol.1910.sp001406. PMC 1512903. PMID 16993030.[permanent dead link]